Table 2 Baseline characteristics: total and by renal evolution at 6 months
Characteristics | Total (n = 73) | No CKD progression (n = 58) | CKD progression (n = 15) | P value |
|---|---|---|---|---|
Continuos variables: average ± SD | ||||
Age of onset (years) | 34.4 ± 15.5 | 32.2 ± 13.9 | 44.4 ± 19.1 | 0.024* |
SLEDAI | 16.1 ± 7.3 | 16.7 ± 7.7 | 13.9 ± 5.2 | 0.179 |
Creatinine (mg/dl) | 1.12 ± 0.81 | 1.04 ± 0.76 | 1.41 ± 0.94 | 0.041* |
Glomerular filtrate rate (ml/min/1.73m2) | 84.3 ± 4.7 | 88.3 ± 5.2 | 69.8 ± 9.8 | 0.106 |
Proteinuria (g/24 h) | 3.51 ± 3.45 | 3.83 ± 3.76 | 2.35 ± 1.55 | 0.155 |
Renal activity index | 4.56 ± 3.84 | 4.58 ± 4.09 | 4.47 ± 2.75 | 0.804 |
Chronicity activity index | 1.34 ± 1.59 | 1.05 ± 1.26 | 2.47 ± 2.20 | 0.015* |
Categorical variables: n (%) | ||||
Woman | 60 (82.2%) | 50 (86.2%) | 10 (66.7%) | 0.078 |
Ethnicity | ||||
Caucasian | 48 (70.6%) | 38 (70.4%) | 10 (71.4%) | |
Asian | 2 (2.9%) | 2 (3.7%) | – | |
Arab | 2 (2.9%) | 2 (3.7%) | – | |
Hispanic | 14 (20.6%) | 11 (20.4%) | 3 (21.4%) | |
Others | 2 (2.9%) | 1 (1.8%) | 1 (7.1%) | |
Extrarenal manifestations | 53 (75.7%) | 41 (73.2%) | 12 (85.7%) | 0.492 |
Haemolytic anaemia | 7 (10.3%) | 5 (9.1%) | 2 (15.4%) | 0.611 |
CNS diffuse involvement | 7 (10.0%) | 7 (12.5%) | – | 1.331 |
Thrombocytopenia (< 50.000) | 8 (11.8%) | 4 (7.3%) | 4 (30.7%) | 0.038* |
Haematuria | 56 (80.0%) | 43 (78.2%) | 13 (86.7%) | 0.718 |
Cell casts | 32 (49.2%) | 27 (50.0%) | 5 (45.4%) | 0.783 |
Histology type | 0.031* | |||
No proliferative (mesangial and membranous) | 16 (22.2%) | 16 (28.1%) | – | |
Proliferative | 56 (77.8%) | 41 (71.9%) | 15 (100%) | |
Anti-DNA antibodies | 52 (76.5%) | 41 (75.9%) | 11 (78.6%) | 1.000 |
Lupus anticoagulant | 10 (20.0%) | 8 (18.6%) | 2 (28.6%) | 0.616 |
Anticardiolipins (Ig G or Ig M) | 15 (29.4%) | 12 (29.7%) | 3 (30.0%) | 1.000 |
Anti β2 glycoproteins (Ig G/Ig M) | 2 (7.7%) | 2 (9.5%) | – | 1.000 |
Low C3 | 47 (67.1%) | 40 (72.7%) | 7 (46.7%) | 0.057 |
Low C4 | 45 (64.3%) | 36 (65.4%) | 9 (60.0%) | 0.696 |
Interstitial fibrosis | ||||
No | 45 (61.6%) | 40 (69.0%) | 5 (33.3%) | |
Yes | 28 (38.4% | 18 (31.0%) | 10 (66.7%) | |
Tubular atrophy | ||||
No | 44 (66.1%) | 39 (68.4%) | 5 (33.3%) | |
Yes | 28 (38.9%) | 18 (31.6%) | 10 (66.7%) | |
Thrombotic microangiopathy | – | – | – | |
Previous antimalarial treatment | 22 (32.8%) | 19 (34.5%) | 3 (25.0%) | 0.737 |
Previous glucocorticoids treatment | 42 (60.9%) | 36 (64.3%) | 6 (46.1%) | 0.228 |
Previous immunosuppressor treatment | 18 (26.1%) | 14 (25.0%) | 4 (30.8%) | 0.670 |